// Xue Cai 1 and Michael E. Sughrue 1 1 Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA Correspondence to: Michael E. Sughrue, email: michael-sughrue@ouhsc.edu Keywords: glioblastoma; molecular mechanisms; gene therapy; immunotherapy; CRISPR/Cas9 genome editing Received: August 11, 2017 Accepted: December 08, 2017 Published: December 20, 2017 ABSTRACT Glioblastoma (GBM) is the most invasive and devastating primary brain tumor with a median overall survival rate about 18 months with aggressive multimodality therapy. Its unique characteristics of heterogeneity, invasion, clonal populations maintaining stem cell-like cells and recurrence, have limited responses to a variety of therapeutic approaches, and have made GBM the most difficult brain cancer to treat. A great effort and progress has been made to reveal promising molecular mechanisms to target therapeutically. Especially with the emerging of new technologies, the mechanisms underlying the pathology of GBM are becoming more clear. The purpose of this review is to summarize the current knowledge of molecular mechanisms of GBM and highlight the novel strategies and concepts for the treatment of GBM.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: